Franzius C, Sciuk J, Brinkschmidt C, Jürgens H, Schober O
Department of Nuclear Medicine, University Hospital, Westfälische Wilhelms-Universität, Münster, Germany.
Clin Nucl Med. 2000 Nov;25(11):874-81. doi: 10.1097/00003072-200011000-00004.
The purpose of this study was to evaluate the potential of positron emission tomography using F-18-fluoro-2-deoxy-D-glucose (FDG PET) to assess the chemotherapy response of primary osseous tumors compared with the degree of necrosis determined histologically.
Seventeen patients with primary bone tumors (11 osteosarcomas, 6 Ewing's sarcomas) were examined using FDG PET and planar bone scintigraphy before neoadjuvant chemotherapy and before surgery. Tumor response was classified histologically according to Salzer-Kuntschik (grades I-II: good response; grades IV-VI: poor response). In both imaging methods, quantification was performed using tumor to nontumor ratios (T:NT).
Histologically, 15 patients were classified as having good responses (grade I, n = 1; grade II, n = 6; grade III, n = 8) and two as having poor responses (grades IV and V). FDG PET showed more than a 30% decrease in T:NT ratios in all patients who had good responses. However, three of these patients had increasing bone scintigraphy T:NT ratios, and another five had decreasing ratios of less than 30%. The patients with poor responses had increasing T:NT ratios and decreasing ratios of less than 30%, respectively, using both imaging methods.
FDG PET seems to be a promising tool for evaluating the response of primary osseous tumors to chemotherapy. In this preliminary study, FDG PET was superior to planar bone scintigraphy.
本研究旨在评估使用F-18-氟-2-脱氧-D-葡萄糖(FDG PET)进行正电子发射断层扫描与组织学确定的坏死程度相比,评估原发性骨肿瘤化疗反应的潜力。
17例原发性骨肿瘤患者(11例骨肉瘤,6例尤因肉瘤)在新辅助化疗前和手术前接受了FDG PET和平面骨闪烁扫描检查。根据Salzer-Kuntschik对肿瘤反应进行组织学分类(I-II级:反应良好;IV-VI级:反应较差)。在两种成像方法中,均使用肿瘤与非肿瘤比值(T:NT)进行定量分析。
组织学上,15例患者被分类为反应良好(I级,n = 1;II级,n = 6;III级,n = 8),2例反应较差(IV级和V级)。FDG PET显示所有反应良好的患者T:NT比值下降超过30%。然而,其中3例患者的骨闪烁扫描T:NT比值升高,另外5例患者的比值下降小于30%。反应较差的患者在两种成像方法中T:NT比值分别升高和下降小于30%。
FDG PET似乎是评估原发性骨肿瘤化疗反应的一种有前景的工具。在这项初步研究中,FDG PET优于平面骨闪烁扫描。